DHR: Leadership change · Company disclosure · Other company developments

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS Appointment of Julie Sawyer Montgomery as President and Chief Executive Officer On August 3, 2026, Danaher Corporation (the “Company” or “Danaher”) announced that, effective as of October 1, 2026 (the “Effective Date”), the Board of Directors of the Company (the “Board”) has appointed Julie Sawyer Montgomery as President and Chief Executive Officer of the Company (the “CEO”). The Board also appointed Ms. Sawyer Montgomery to the Board and to each of the Executive, Finance and Science & Technology Committees of the Board, in each case effective as of the Effective Date. There are no arrangements or understandings between Ms. Sawyer Montgomery and any other person pursuant to which Ms. Sawyer Montgomery was selected as an officer or director of the Company, and there are no family relationships between Ms. Sawyer Montgomery and any director or executive officer of the Company. There are no transactions in which Ms. Sawyer Montgomery has an interest requiring disclosure under Item 404(a) of Regulation S-K. Ms. Sawyer Montgomery previously entered into an indemnification agreement with the Company, the form of which is disclosed as Exhibit 10.30 to Danaher’s Annual Report on Form 10-K for the year ended December 31, 2025, and which is incorporated by reference herein. Biographical Information Since joining the Company in 2017, Ms. Sawyer Montgomery, age 54, has served in a series of progressively more responsible general management positions (and as a Danaher officer since 2024), including as President of Danaher’s Beckman Coulter Diagnostics subsidiary from January 2020 to December 2022, as Vice President – Group Execut